GNFT 财务： Genfit SA AI 分析

主页

股票

GNFT

财务数据

GNFT 财务

Genfit SA

$8.95

4.06%

$0.34

收盘价：Apr 02, 16:00:00 GMT-4

$8.95

盘后：Apr 02, 20:00:00 GMT-4

概述预测收益股息财务数据

收入

资产负债表

现金流量

年度

季度性

GNFT 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
营收	45	70	38	26	85	7
营收同比增长 (YoY)	-46%	84%	46%	-69%	1,114%	-83%
营收成本	2	2	2	2	1	2
毛利润	43	68	36	24	84	5
销售、一般及管理费用	8	8	8	7	8	18
研发	40	34	35	27	27	50
营业费用	71	65	62	51	51	83
其他非经营性收入 (费用)	-8	0	1	0	0	0
税前利润	-39	1	-28	-23	69	-101
所得税费用	0	0	0	0	2	0
净利润	-38	1	-28	-23	67	-101
净利润增长	-273%	-104%	22%	-134%	-166%	55%
稀释后流通股数	49.78	49.94	49.7	49.67	55.61	38.85
股份同比变动 (YoY)	-18%	0%	0%	-11%	43%	5%
每股收益 (摊薄)	-0.77	0.03	-0.58	-0.47	1.2	-2.6
每股收益增长率	-314%	-105%	22%	-139%	-146%	48%
自由现金流	-6	14	-57	-72	99	-97
每股自由现金流	--	--	--	--	--	--
毛利率	95.55%	97.14%	94.73%	92.3%	98.82%	71.42%
营业利润率	-60%	4.28%	-68.42%	-103.84%	37.64%	-1,100%
净利率	-84.44%	1.42%	-73.68%	-88.46%	78.82%	-1,442.85%
自由现金流利润率	-13.33%	20%	-150%	-276.92%	116.47%	-1,385.71%
EBITDA	-26	4	-25	-26	34	-74
EBITDA 利润率	-57.77%	5.71%	-65.78%	-100%	40%	-1,057.14%
EBITDA 中的折旧与摊销	1	1	1	1	2	3
EBIT	-27	3	-26	-27	32	-77
EBIT 利润率	-60%	4.28%	-68.42%	-103.84%	37.64%	-1,100%
有效税率	0%	0%	0%	0%	2.89%	0%

Follow-Up Questions

Genfit SA 的关键财务报表是什么？



根据最新的财务报表（Form-10K），Genfit SA 的总资产为 $151，净利润为 $1

GNFT 的关键财务比率是什么？



Genfit SA 的流动比率是 1.84，净利 margin 为 1.42，每股销售为 $1.4。

Genfit SA 的收入按细分市场或地理位置如何划分？



Genfit SA 最大收入来源是 Innovative Medicines and Diagnostic Solutions，在最近的收益报告中收入为 67,001,999。就地区而言， France 是 Genfit SA 的主要市场，收入为 67,001,999。

Genfit SA 是否盈利？



是的，根据最新的财务报表，Genfit SA 的净利润为 $1

Genfit SA 有负债吗？



是的，Genfit SA 的负债为 82

Genfit SA 的流通股有多少？



Genfit SA 的总流通股为 49.99

关键数据

前收盘价

$8.6

开盘价

当日区间

$8.85 - $9

52周范围

$2.55 - $8.95

交易量

4.2K

平均成交量

9.8K

股息收益率

每股收益（TTM）

-0.90

市值

$447.5M

什么是 GNFT？

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 188 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

功能特性

资源